Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 29, 2017 | Series B | $114M | 2 | — | — | Detail |
Mar 23, 2017 | Series Unknown | — | 1 | — | — | Detail |
Mar 24, 2015 | Series A | $44M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Medtronic | — | Series B |
ARCH Venture Partners | — | Series B |